PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline

Overview of attention for article published in Journal of Clinical Oncology, August 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 40 news outlets
twitter: 97 X users
facebook: 2 Facebook pages

f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 67 news stories from 40 outlets.

Evaluating Toxicities of Antineoplastic Drug Therapeutics: Is It Time for a Critical Review?

OncLive, 24 Jul 2023

Maurie Markman, MD An evaluation of the utility of a cancer therapeutic in a clinical trial is determined through metrics that…

Precision Medicine Takes On an Increasingly Relevant but Misunderstood Role in Oncology

OncLive, 28 Mar 2023

Maurie Markman, MD Regulatory approvals of novel antineoplastic agents based on demonstrated meaningful clinical activity in a…

ASCO Addresses PARP Controversy in Guideline Update

MedPage Today, 27 Sep 2022

Oncology/Hematology > Ovarian Cancer A response to "practice-changing data" in the first- and second-line setting by Mike…

The Language of Science Is No Longer Just for Clinicians

OncLive, 22 Mar 2022

Maurie Markman, MD, discusses the expansion and overlap of the language of science within different medical disciplines and the…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 63 additional news stories.